Case description {#sec1-2045894019896677}
================

A 52-year-old female patient with hereditary haemorrhagic telangiectasia (HHT) presented with dyspnoea. She had been diagnosed with HHT with repeated nasal bleeding, mucocutaneous telangiectasia on tongue and nose, multiple arteriovenous malformations (AVMs) (lung and liver) and family history and was being followed up. One year before presentation, she had developed heart failure with lower limb oedema and was treated with diuretics at another hospital. She had also undergone coil embolization for pulmonary haemorrhage due to pulmonary AVMs at a general hospital six months previously. However, she experienced persistent dyspnoea and was diagnosed with pulmonary hypertension (PH). Despite specific treatment of PH with bosentan, sildenafil, and dobutamine, no improvement was noted in her condition. Following this, she was referred to our centre, for specialised treatment of PH. She was in World Health Organization functional class IV and had dyspnoea at rest. Her oxygen saturation was 97% with high flow nasal oxygen support. We performed a right heart catheterization to assess her haemodynamic status. Her mean pulmonary arterial pressure was 38 mm Hg with a pulmonary capillary wedge pressure of 10 mmHg and a right atrial pressure of 22 mm Hg. Her cardiac output was 9.0 L/min, and her pulmonary vascular resistance was 3.2 Wood units ([Fig. 1a](#fig1-2045894019896677){ref-type="fig"}). Oxygen sampling by catheter revealed an increase in oxygen saturation in the inferior vena cava from 61 to 91% between the supra- and the infra-hepatic veins. As shown in [Fig. 1b](#fig1-2045894019896677){ref-type="fig"} and [c](#fig1-2045894019896677){ref-type="fig"}, a time-dependent change was observed in the morphology of the liver AVMs on computed tomography scans. The suspicion of extensive proliferation of AVMs was confirmed by contrast-enhanced computed tomography angiography ([Fig. 1d](#fig1-2045894019896677){ref-type="fig"} and [e](#fig1-2045894019896677){ref-type="fig"}). Based on these findings and haemodynamic data, we considered the persistence of PH to be due to extreme arteriovenous shunt in the liver through the AVMs. Although previous study had reported that bevacizumab could be an effective treatment for HHT patients with liver AVMs, it was not approved in Japan.^[@bibr1-2045894019896677]^ Following discussions with hepatologists and transplant surgeons, we adjudged that liver transplantation (LT) was essential for the treatment of this condition. She was registered as an LT recipient, with a requirement for urgent LT. In the meantime, we considered that the high flow through the liver also results in elevated central mixed venous saturations that mimic those seen with atrial septal defects and other large intra-cardiac left-to-right shunts. Thereafter, we recalculated her haemodynamics using the average oxygen saturation in superior and inferior vena cava, inferior to the hepatic vein. By mixed venous oxygen saturation 61%, we estimated that her actual systemic output was reduced with 2.5 L/min. As per the results, we considered that more PH-specific therapy could increase her actual output and decrease her pulmonary arterial pressure that reduces her perioperative risk during LT, whereas it involved taking risks to increase AV shunt flow. Hence, we decided to switch PAH drug. Simultaneously, we also administered increasing diuretics to reduce any AV shunt flow. However, no significant improvement was observed in her condition even after the initiation of heart failure and PH-specific therapy ([Fig. 1a](#fig1-2045894019896677){ref-type="fig"}). Eleven months after the initial presentation, she underwent a successful cadaveric LT. Intraoperative monitoring revealed a dramatic reduction in the central venous pressure from 21 to 4 mmHg after LT. Postoperative right heart catheterization revealed a remarkable haemodynamic improvement ([Fig. 1a](#fig1-2045894019896677){ref-type="fig"}). Her symptoms improved to World Health Organization functional class I. She was continued on treatment with tadalafil and is being followed up regularly. Fig. 1.Haemodynamic data pre- and post-liver transplantation and arteriovenous malformations in the liver. A significant improvement in haemodynamic parameters was observed after liver transplantation compared to pre-transplant values (a). Compared with one year previously (b), low-density areas in the liver had enlarged on computed tomography scan indicating worsening of arteriovenous malformations (c). Contrast-enhanced computed tomography and angiography shows major shunt caused by arteriovenous malformations in the liver (d and e).PH: pulmonary hypertension; PCWP: pulmonary capillary wedge pressure; PAP: pulmonary arterial pressure; RAP: right atrial pressure; O~2~: oxygen; SVC: superior vena cava; IVC: inferior vena cava; Qp: pulmonary blood flow; Qs: systemic blood flow.\*Haemodynamic data were adjusted because right heart catheter in the referred patient was performed under oxygen inhalation and the continuous injection of dobutamine 3γ.^†^PAP is presented as systolic/diastolic (mean) pulmonary artery pressure.^‡^Cardiac output is calculated using the average oxygen saturation in SVC and IVC, inferior to the hepatic vein as mixed venous oxygen saturation.

Discussion {#sec2-2045894019896677}
==========

In this case report, we describe the haemodynamic changes before and after specific treatment for PH and after LT in a patient with HHT. Detailed hemodynamic data were not presented in previous reports.^[@bibr2-2045894019896677],[@bibr3-2045894019896677]^ HHT or Rendu-Osler-Weber syndrome is a systemic vascular disease leading to the formation of AVMs in the nose, mouth, brain, lungs, liver, gastrointestinal tract, and the skin.^[@bibr4-2045894019896677]^ Various mutations in genes -- such as *ENG*, encoding endoglin, and *ACVRL1*, encoding activin receptor-like kinase -- are frequently associated with HHT. Such mutations are components of the receptor complexes for growth factors of the transforming growth factor superfamily. Hence, mediated angiogenic factors such as the vascular endothelial growth factor are believed to be involved in the expression of AVMs.^[@bibr1-2045894019896677],[@bibr4-2045894019896677]^ A significant variation exists among patients in the AVM phenotype; however, the associated brain and pulmonary lesions lead to substantial morbidity and mortality. HHT is sometimes complicated with PH. There are some mechanisms for the development of PH in patients with HHT. PH commonly occurs due to a high output caused by AVMs in organs such as the liver, frequently complicated by left heart failure. Rarely, pulmonary arterial hypertension may be due to pulmonary vascular angiopathy.^[@bibr2-2045894019896677]^ In addition, HHT patients with the setting of liver cirrhosis and portal hypertension may cause portopulmonary hypertension. In our patient, major arteriovenous shunting was observed through AVMs in the liver with a mild increase in the pulmonary vascular resistance and left heart failure. Hence, we considered extensive shunt through AVMs in the liver to be the mechanism of causation of PH. Hence, LT was essential to treat PH associated with HHT in our patient.^[@bibr5-2045894019896677]^ A previous report suggested that high pulmonary arterial pressure, especially \>35 mm Hg, is a significant perioperative risk factor for LT in patients with portopulmonary hypertension.^[@bibr6-2045894019896677]^ Fortunately, our patient did not have severe but moderate elevation in pulmonary arterial pressure, thus enabling successful LT. Although a significant improvement was noted in her clinical condition postoperatively, she requires careful follow-up for signs of worsening systemic vascular abnormality.

This case report was presented at the 4th Annual Meeting of the Japanese Pulmonary Circulation and Pulmonary Hypertension Society, Hamamatsu, Japan, on 21 June 2019.
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